Kunena :: Тема: Posted by Aiello David on 29.11.2016 17:38:35: is tarceva a cure (1/2)

Навигация: Главная Форум Главный раздел Сообщество базовых площадокPosted by Aiello David on 29.11.2016 17:38:35: is tarceva a cure

Добро пожаловать, Гость

Форум

Главный раздел

Сообщество базовых площадок

Posted by Aiello David on 29.11.2016 17:38:35: is tarceva a cure

Страница:
1
2

ТЕМА: Posted by Aiello David on 29.11.2016 17:38:35: is tarceva a cure

Posted by Aiello David on 29.11.2016 17:38:35: is tarceva a cure 7 года 5 мес. назад #924

akipk

High Quality - Low Cost Anti-Cancer Drugs

*
Shepherd F, Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353. 123. 2005 -132, Medline
Background: Erlotinib (E), a small-molecule EGFR TKI, is proven to extend survival versus placebo (P) in 2nd/3rd-line advanced NSCLC. The phase III SATURN study (BO18192) was initiated to evaluate E as maintenance therapy after standard 1st-line platinum-based chemotherapy (CT) in advanced NSCLC. Methods: Patients with no evidence of disease progression after 4 cycles of CT were randomized to receive either E 150 mg/day or P until progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS) in all patients and the co-primary endpoint was PFS in EGFR immunohistochemistry-positive (IHC+) patients. Results: A total of 1,949 patients entered the CT phase, of whom 889 were randomized to E (n=438) or P (n=451). Median age was 60 years for both arms. Baseline characteristics for E and P arms (%): male/female: 73/27 and 75/25; adenocarcinoma + BAC/squamous-cell/other: 47/38/15 and 44/43/13; stage IIIB/IV: 26/74 and 24/76; Caucasian/Asian/other: 84/14/2 and 83/15/2; ECOG PS 0/1: 31/69 and 32/68; current/former/never smoker: 55/28/18 and 56/27/17. PFS (by investigator assessment; confirmed by independent review) was significantly prolonged with E versus P in all patients (HR 0.71 [95% CI 0.62-0.82]; p<.0001) and in EGFR IHC+ patients (HR 0.69 [95% CI 0.58-0.82]; p<.0001). Subgroup analyses will be reported. Response rate was 12% with E versus 5% with P. Disease control rate (complete response + partial response + stable disease >12 wks) was 40.8% with E versus 27.4% with P (p<.0001). OS data are not yet mature. E was well tolerated: the majority of treatment-related adverse events (AEs) were grade 1/2. AEs reported in ≥10% of all patients were rash (60% with E versus 9% with P) and diarrhea (20% with E versus 5% with P); again, most were grade 1/2. Only 2.3% of patients receiving E had a serious treatment-related AE and 2.8% withdrew due to a treatment-related AE. Conclusions: The SATURN study met its primary and co-primary endpoints with high statistical significance. Erlotinib in the 1st-line maintenance setting is well tolerated, and significantly improves disease control and delays progression versus placebo across patient subgroups.
Before using Erlotinib, ask the following questions to the doctor:
Exposure to chemotherapy was similar between the two treatment arms. The median number of cycles of carboplatin and paclitaxel was five for both arms ( P = .246), whereas respective mean doses per cycle for carboplatin (619.9 mg for erlotinib 635.0 mg for placebo; P = .1) and paclitaxel (358.4 for erlotinib; 362.8 mg for placebo; P = .2) were also similar.
- Pregnant women are excluded from this study because bevacizumab and erlotinib are anti-cancer agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with these agents, breastfeeding should be discontinued if the mother is treated on this study
. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced nonsmall-cell lung cancer. J Clin Oncol 2007 ; 25 ( 7 ): 760 - 766.
www.energoizdelye.ru/forum/28/66101-post...-molecular-structure
TARCEVA ® (erlotinib)
Loss of taste is found among people who take Tarceva, especially for people who are female, 60+ old. have been taking the drug for 1 - 6 months, also take medication Gemzar, and have Lung cancer - non-small cell. We study 19,048 people who have side effects while taking Tarceva from FDA and social media. Among them, 75 have Loss of taste. Find out below who they are, when they have Loss of taste and more.
Dumnezeu sa-l odihneasca in pace pe tatal tau.Am si eu mama bolnava de cancer pulmonar cu metastaze la ficat. Diagnosticul pus de doctor la inceputul bolii. Adenocarcinom bronhopulmonar drept T3N0M0 STII B. A inceput tratamentul cu 3 cicluri citostatice Paclitaxel+CBDCA X3 dar boala a avansat cu metastaze la ficat, i sa oprit acest tratament. Doctorul a zis ca este eligibila pt protocolul 14T-MC-JVBA care de fapt este Docetaxel+ un medicament experimental Ramucirumab din acestea a facut 8 cicluri fara nici un rezultat boala evoluand negativ tratamentul a fost oprit.Au trecut-o pe alt citostatic Gemcitabina a facut 6 sedinte fara nici un rezultat. Mama are 66 de ani o persoana foarte dinamica ea tine toata casa. Dupa citostatice a ajuns de la 70 la58kg, analizele la sange dezastroase, sistemul imunitar distrus si prihic la pamant se simtea foarte rau. Au fost oprite citostaticele iar doctorul de la Cluj ne-a zis ca ar fi bine sa i se faca dosar pt Tarceva. Noi fiind din jud. Alba dosarul trebuia facut de oncologul din Alba. Ne-am dus la d-nul dr Razvan Curca oncolog la Alba Iulia si ne-a facut dosarul pt Tarceva 150mg. Am ramas impresionat de omenia acestui doctor cand a vazut-o pe mama fara sa ne cunoasca si fara a primi ceva de la noi i-a dat mamei pastilele de Tarceva care le avea ramase de la alti bolnavi.Putini doctori mai avem care sa te ajute fara sa le dai ceva. Cu aceste pastile si cu ce ammai cumparat de pe internet de la un Domn din Piatra Neamt( sa-i de-a D-zeu sanatate m-i le-a dat la un pret mic), am reusit sa ajungem pana astazi din iulie de cand i-a Tarceva. Acum mama se simte foarte bine parca a inflorit a ajuns de la 58 la 64kg a revenit si psihic si spera din nou. Dar eu sunt disperat mai are Tarceva pt o zi, am vb cu doctorul si me-a spus ca dosarul nu este aprobat si nu stie cand se va aproba. Medicamentul costa foarte mult in farmacii nu ne permitem sa-l cumparam. Daca ma poate ajuta cineva va rog sa ma contacteze pe nr tel. 0728099622 sa e-mail. Этот адрес электронной почты защищен от спам-ботов. У вас должен быть включен JavaScript для просмотра. .
This randomized, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of onartuzumab (MetMAb) in combination with Tarceva (erlotinib) in participants with incurable non-small cell lung cancer identified to be Met diagnostic-positive. Participants will be randomized to receive either onartuzumab (MetMAb) or placebo in combination with erlotinib. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.
Distribución: Erlotinib tiene un volumen de distribución aparente promedio de 232 L y se distribuye en los tejidos tumorales humanos. En un estudio de 4 pacientes (3 con cáncer de pulmón de células no pequeñas [CPCNP] y 1 con cáncer de laringe) que recibieron TARCEVA ® en dosis de 150 mg diarios por vía oral, las muestras tumorales obtenidas mediante escisión quirúrgica al día 9 de tratamiento revelaron concentraciones promedio de erlotinib en el tumor de 1.185 ng/g de tejido. Esto corresponde a un promedio global de 63% de las concentraciones plasmáticas máximas observadas en estado estacionario. Los principales metabolitos activos estaban presentes en el tumor en concentraciones promedio de 160 ng/g de tejido, lo que corresponde a un promedio global de 113% de las concentraciones plasmáticas máximas observadas en el estado estacionario.
Kasthuri I can understand your fear of the tarceva flare. All I can tell ou is that after 2.5 years on tarceva my cancer didn’t flare when I stopped.
www.luckyday.su/index.php/forum/fludim-t...rlotinib-launch-date
Eligibility criteria included International Federation of Gynecology and Obstetrics stage IIB to IIIB epidermoid cervical cancer, no prior therapy, and an Eastern Cooperative Oncology Group performance status of 0 to 2. Patients received erlotinib at a dose of 150 mg/day 1 week before and in combination with cisplatin (40 mg/m 2 administered weekly for 5 cycles) and radiotherapy (4500 centigrays in 25 fractions), followed by brachytherapy (4 fractions at a dose of 600 centigrays weekly).
forum.drujba-konserv.com/viewtopic.php?p=12528#12528
The best therapy for those who have initially responded to erlotinib and have subsequently lost their response either through development of the T790M mutation or another resistance mechanism, remains another area of active research. Hopefully at least one of the newer TKIs in development will help in this situation.
Erlotinib is metabolized hepatically. Caution should be used in patients with hepatic insufficiency.
TG101348 sensitizes erlotinib-resistant NSCLC cells to the cytotoxicity of erlotinib
8. The erlotinib saccharinate of claim 2, characterized by a DSC thermogram substantially as depicted in Figure 2.
The serum concentration of Erlotinib can be increased when it is combined with Tolvaptan.
www.school55uu.ru/forum/dobro-pozhalovat...de-effect-of-tarceva
Tarceva et cancer du poumon
2 thoughts on “Dateline: Tarcevaland, December 13, 2013”
You must seek immediate medical help if you see any of the following rare but still very serious side effects while taking erlotinib: shortness of breath getting worse or violent spells of coughing.
Re: Sos quelqu'un connait-il tarceva?
La paroniquia se presenta como dolor, eritema y proliferación de tejido de granulación alrededor de varias uñas de los pies y/o de las manos que simula una uña encarnada. Puede aparecer desde las 4 semanas hasta después de 12 meses de tratamiento con gefitinib 8 y es frecuente la sobreinfección secundaria 32 . Se ha tratado con baños antisépticos y astringentes, antibióticos tópicos o sistémicos e incluso con escisión parcial de la lámina ungueal, aunque esto último no parece eficaz 8 , 33 , 34 . En nuestros casos la aplicación de nitrato de plata fue de ayuda para reducir el tejido de granulación. Debido al intenso dolor, que puede dificultar la deambulación, puede ser necesaria la interrupción temporal de erlotinib.
Here, we report a case showing a positive response to erlotinib treatment in the second-line setting. The patient, an elderly male smoker with stage iv nsclc. had a tumour that was EGFR mutation-negative (wild-type EGFR ). Based on this clinical case, we discuss the controversy concerning the need for, and impact of, testing for EGFR mutation after first-line treatment.
Tarceva(R) (erlotinib) has been shown not only to improve survival by an impressive 42.5% but also to improve disease symptoms and quality of life for patients suffering from NSCLC, the most common form of lung cancer. Today's approval is an important step forward in the fight against this deadly disease - a disease which worldwide claims one life every thirty seconds (1) and currently has very few treatment options.
www.housestroika.ru/index.php/forum/razd...tarceva-quanto-custa
"All the indications were showing that the Iressa wasn't working, that she wasn't getting any benefit from it," Dr. Shore said. But in January, Ms. Blue learned her first Tarceva prescription would cost $2,800 -- not because she had switched drugs, but because of Part D's rules requiring co-payments.
friendsknock.com/index.php?do=/blog/3631...or-sale-philippines/
There is data surrounding the efficacy of tarceva for SqCC. The efficacy is modest, but real.
ASCO recently held their 43rd conference and released hundreds of new studies on cancer treatment. One of them does cover Erlotinib as a first line treatment for NSCL.
Experimental: ARQ 197 and erlotinib
Tarceva may cause a skin rash or other skin problems. Exposure to sunlight may increase your odds of developing a rash.
(This list is NOT a complete list of side effects reported with Tarceva. Your health care provider can discuss with you a more complete list of side effects.).
Age of people who have Dizziness when taking Tarceva *:
foodtube.net/profiles/blogs/posted-by-su...9-36-tarceva-farmaco
The most common adverse reactions in pancreatic cancer patients receiving TARCEVA 100 mg plus gemcitabine were fatigue, rash, nausea, anorexia and diarrhea. In the TARCEVA plus gemcitabine arm, Grade 3-4 rash and diarrhea were each reported in 5% of patients. The median time to onset of rash and diarrhea was 10 days and 15 days, respectively. Rash and diarrhea each resulted in dose reductions in 2% of patients, and resulted in study discontinuation in up to 1% of patients receiving TARCEVA plus gemcitabine. Severe adverse reactions ( ≥ Grade 3 NCI-CTC) in the TARCEVA plus gemcitabine group with incidences < 5% included syncope. arrhythmias, ileus. pancreatitis. hemolytic anemia including microangiopathic hemolytic anemia with thrombocytopenia, myocardial infarction /ischemia. cerebrovascular accidents including cerebral hemorrhage, and renal insufficiency [see WARNINGS AND PRECAUTIONS ].
How you take erlotinib
Does Erlotinib have any interaction with Diseases
Erlotinib inhibited cell proliferation and cell cycles in DiFi cells. In HiFi cells, erlotinib partially blocked cell cycles in the G 1 phase and the production of apoptotic cells was observed.
"Smar" targeted photosensitizer conjugated with small molecule target-based anticancer drug which has a simple chemical structure and high stability, is a new promising targeted therapeutic strategy. We herein extended this strategy and reported a novel series of zinc(II) phthalocyanine-erlotinib analogue conjugates with different peripheral substituted positions and lengths of the linker. Having erlotinib analogue as the targeting moiety, all conjugates exhibited high specificity and potent affinity to HepG2 cancer cells and kept high photodynamic activity (IC 50 =3.7–16.7 nmol/L). Structure-activity relationships of these conjugates were assessed by investigating their photophysical/photochemical properties, targeting intracellular uptake and in vitro phototoxicity. The results suggested that α -substituted conjugates showed slightly higher photodynamic activity than β -substituted ones. In conclusion, we have developed a series of promising anticancer agents with high tumor selectivity and anticancer activity for targeted photodynamic therapy.
Because of the strong association of PD-1 / PD-L1 expression and KRAS or EGFR mutations, we further investigated the potential effect of such biomarkers on sensitivity to anti-EGFR agents. With such purpose we analysed the outcome of 99 patients treated with gefitinib or erlotinib. EGFR-TKIs were given as front-line therapy in 29 patients including 26 EGFR mutated patients, and in second or subsequent lines of therapy in 70 individuals, including 29 EGFR mutated, 16 KRAS mutated and 25 triple negative. EGFR-TKIs were offered in the second or further lines of treatment in patients with KRAS mutations or in triple negative according to clinical practice ( Kim et al . 2008 ; Shepherd et al . 2009 ; Cappuzzo et al . 2010 ). In the group of patients treated with erlotinib or gefitinib response rate (RR) was 47.5 %. median TTP 7.9 months and median OS 18.0 months.
Therefore, for patients for whom side effects of Tarceva seem challenging might face more difficulty with Dacomitinib treatment. Nonetheless, the results of PFS were promising enough and provide a greater efficacy in several clinical and molecular subgroups targeting a larger population than Tarceva. Authors, thus, suggested a larger, randomized phase III trial with the same design.